skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration
With the upcoming approval of the first medications targeting NASH (non-alcoholic steatohepatitis) patients, the market value is predicted to reach over US$7.5bn by 2025. Our latest infographic reveals more information about the current drugs in development and the estimated increase in sales that will occur over the next few years.

Since there are currently no approved medications for the treatment of NASH, the first medications that are approved will be highly sought after in the industry.
See at a glance:

 

  • See how much the US market will account for in terms of NASH patients and NASH sales by 2025
  • See the predicted 2025 NASH sales by country (UK, USA, SPAIN, Germany, France, Italy) The
  • See the expected uptake of the pipeline medications

Gain more insights on the market by downloading your complimentary infographic on Non-alcoholic steatohepatitis (NASH) today

DMHC NASH Infographic

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: